KRAS - Wikipedia
KRAS (Kirsten rat sarcoma virus) is a gene that provides instructions for making a protein called K-Ras, a part of the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus.
KRAS mutation: from undruggable to druggable in cancer
2021年11月15日 · Kirsten rat sarcoma viral oncogene homologue (KRAS) is the best-known oncogene with the highest mutation rate among all cancers and is associated with a series of highly fatal cancers,...
Targeting KRAS in cancer - Nature Medicine
2024年4月18日 · KRAS is a small membrane-bound GTP hydrolase protein that cycles between ‘on’ (GTP-loaded) and ‘off’ (GDP-unloaded) states. This cycling between the ‘on’ and ‘off’ state depends on the...
What’s new in KRAS mutation research? - MD Anderson Cancer …
2024年4月4日 · Cancer cells often develop genetic mutations that initiate and sustain the growth of tumors. The most frequently mutated of these oncogenic driver genes, called KRAS, is associated with some of the most fatal cancer types: lung, pancreatic and colorectal cancers.
Targeting the KRAS mutation for more effective cancer …
2021年2月12日 · KRAS mutations are present in approximately 25% of tumors, making them one of the most common gene mutations linked to cancer. They are frequent drivers in lung, colorectal and pancreatic cancers. KRAS drives 32% of lung cancers, 40% of colorectal cancers, and 85% to 90% of pancreatic cancer cases.
KRAS gene - MedlinePlus
The KRAS gene provides instructions for making a protein called K-Ras that is part of a signaling pathway known as the RAS/MAPK pathway. The protein relays signals from outside the cell to the cell's nucleus.
Sotorasib is First KRAS Inhibitor Approved by FDA - NCI
2021年6月25日 · The CodeBreaK 100 trial, funded by Amgen and NCI, is testing sotorasib (previously called AMG510) as a treatment for people with solid tumors that have KRAS G12C. The mutation, a hallmark of damage from cigarette smoke, is most common in lung cancer.
KRAS: From undruggable to a druggable Cancer Target
In this review article, we provide an overview on the role of K-RAS in tumorigenesis, past approaches to inhibiting Kras, and current and future prospects for targeting Kras.
Oncogenic KRAS: Signaling and Drug Resistance - PMC
KRAS is one of the oncogenic proteins and best well-known GTPase proteins. Although KRAS serves as regulation of cellular process, abnormal mutated and GTP-bound KRAS is highly expressed in human cancers. Understanding biological characteristics and ...
KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance
KRAS is a small GTPase that is among the most commonly mutated oncogenes in cancer. Here, we discuss KRAS biology, therapeutic avenues to target it, and mechanisms of resistance that tumors employ in response to KRAS inhibition.